Loading...
Loading...
STTK| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 1.1M |
| Gross Profit | -1.0M |
| Operating Expense | 21.7M |
| Operating I/L | -21.7M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.0M |
| Pretax | -20.7M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | -19.8M |
Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for cancer and autoimmune diseases. The company's primary focus is on its lead product candidate, SL-172154, currently in Phase 1 clinical trials for ovarian, fallopian tube, and peritoneal cancers. Additionally, it is developing SL-279252, also in Phase 1 clinical trials for advanced solid tumors and lymphoma. Shattuck Labs, Inc. generates revenue through the development and potential commercialization of these innovative therapeutics for the treatment of cancer and autoimmune diseases.
